Morphic Holding Inc MORF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MORF is a good fit for your portfolio.
News
-
Morphic Holding, Inc. (MORF) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
-
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Morphic Holding, Inc. (MORF) on Behalf of Investors
-
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Morphic Holding, Inc. (MORF) on Behalf of Investors
-
The Law Offices of Frank R. Cruz Announces Investigation of Morphic Holding, Inc. (MORF) on Behalf of Investors
Trading Information
- Previous Close Price
- $34.45
- Day Range
- $33.82–35.51
- 52-Week Range
- $19.33–63.02
- Bid/Ask
- $35.07 / $35.14
- Market Cap
- $1.76 Bil
- Volume/Avg
- 82,162 / 496,824
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2,798.21
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Morphic Holding Inc is a biopharmaceutical company applying its insights into integrins to discover and develop a pipeline of oral small-molecule integrin therapeutics. Integrins are a target class with multiple approved injectable blockbuster drugs for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 121
- Website
- https://www.morphictx.com
Comparables
Valuation
Metric
|
MORF
|
CBAY
|
PLRX
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.45 | 12.65 | 1.84 |
Price/Sales | 2,798.21 | 111.01 | 540.73 |
Price/Cash Flow | — | — | — |
Price/Earnings
MORF
CBAY
PLRX
Financial Strength
Metric
|
MORF
|
CBAY
|
PLRX
|
---|---|---|---|
Quick Ratio | 28.43 | 10.70 | 17.43 |
Current Ratio | 28.94 | 10.96 | 17.72 |
Interest Coverage | — | −5.27 | −145.34 |
Quick Ratio
MORF
CBAY
PLRX
Profitability
Metric
|
MORF
|
CBAY
|
PLRX
|
---|---|---|---|
Return on Assets (Normalized) | −19.79% | −30.06% | −22.68% |
Return on Equity (Normalized) | −20.47% | −51.97% | −24.50% |
Return on Invested Capital (Normalized) | −23.98% | −30.87% | −28.46% |
Return on Assets
MORF
CBAY
PLRX
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Jnpxnjvpfd | Tgzrn | $571.0 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Jcyqgyck | Bqqvzw | $107.8 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Hwkwtwx | Rzzftc | $106.1 Bil | |
MRNA
| Moderna Inc | Xvdnpvx | Xqvn | $42.3 Bil | |
ARGX
| argenx SE ADR | Nysthmrzm | Jlfl | $23.7 Bil | |
BNTX
| BioNTech SE ADR | Cnqddqb | Rsryf | $22.1 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Rhvfzmcyn | Jjzjdq | $19.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Srfvtbff | Vrvbzg | $16.7 Bil | |
RPRX
| Royalty Pharma PLC Class A | Xjwsppmqs | Swffpc | $13.6 Bil | |
INCY
| Incyte Corp | Stttjhph | Mtsgvlz | $12.8 Bil |